Centessa Pharmaceuticals (CNTA) to Release Earnings on Thursday

Centessa Pharmaceuticals (NASDAQ:CNTA) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter.

Centessa Pharmaceuticals Trading Up 1.6 %

Shares of CNTA stock opened at $16.77 on Thursday. Centessa Pharmaceuticals has a 12 month low of $7.75 and a 12 month high of $19.09. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The business’s 50 day moving average is $16.46 and its two-hundred day moving average is $16.36. The company has a market cap of $2.21 billion, a PE ratio of -10.96 and a beta of 1.54.

Wall Street Analysts Forecast Growth

CNTA has been the topic of several analyst reports. TD Cowen initiated coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating for the company. Morgan Stanley reissued an “overweight” rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Finally, Guggenheim reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $26.00.

Insider Activity

In related news, General Counsel Iqbal J. Hussain sold 6,000 shares of the firm’s stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total value of $91,740.00. Following the completion of the transaction, the general counsel now directly owns 118,265 shares of the company’s stock, valued at $1,808,271.85. This trade represents a 4.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $17.44, for a total value of $959,200.00. Following the completion of the transaction, the chief executive officer now directly owns 520,661 shares of the company’s stock, valued at approximately $9,080,327.84. This trade represents a 9.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 260,168 shares of company stock valued at $4,357,818. 11.59% of the stock is owned by company insiders.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.